Business Context and Reporting Period
This Form 8-K Current Report was filed by Illumina, Inc. on June 16, 2026. The filing reports a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial performance data.
Material Changes
The Board of Directors increased its size from nine to ten members. Daniel M. Skovronsky, M.D., Ph.D., was appointed as a new independent director, effective immediately. Dr. Skovronsky is scheduled to stand for election at the 2027 annual meeting of stockholders for a one-year term.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No risks, contingencies, or unusual items were disclosed in this specific report. Dr. Skovronsky is not a party to any reportable transactions with the Company and will participate in the standard non-employee director compensation program.
Investor Verification Checklist
- Verify Dr. Skovronsky's professional background and independence status.
- Review the attached press release (Exhibit 99.1) for additional context on the appointment.
- Confirm the updated Board composition in subsequent proxy statements.
- Note that this filing does not impact current financial statements or operational metrics.